Collection of biological samples for diagnosing rare neurological diseases
Control Cohort CTRL COH
This study is collecting blood and spinal fluid samples from people with rare neurological diseases to see if they can find new markers that help diagnose these conditions more accurately.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 350 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Hospices Civils de Lyon Academic / other |
| Locations | 1 site (Bron) |
| Trial ID | NCT05370079 on ClinicalTrials.gov |
What this trial studies
This study focuses on collecting biological samples, such as blood and cerebrospinal fluid, from patients with various neurological and autoimmune conditions. The aim is to identify new genetic biomarkers that could lead to more accurate diagnostic tools for autoimmune encephalitis and paraneoplastic neurological syndromes. By gathering samples from a diverse group of patients, the study seeks to enhance the understanding of these rare diseases and improve diagnostic capabilities.
Who should consider this trial
Good fit: Ideal candidates for this study include patients diagnosed with Parkinson's disease, amyotrophic lateral sclerosis, glioblastoma, certain cancers without neurological disease, or rheumatoid arthritis.
Not a fit: Patients with neurological disorders that are compatible with paraneoplastic neurological syndrome or autoimmune encephalitis may not benefit from this study.
Why it matters
Potential benefit: If successful, this research could lead to more precise and timely diagnoses for patients suffering from rare neurological diseases.
How similar studies have performed: While the approach of identifying new biomarkers is common, the specific focus on these rare diseases may present novel insights, as similar studies have had varying degrees of success.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * patient with consent * patient with following disease: Parkinson's disease, Amyotrophic lateral sclerosis, Glioblastoma, cancer without neurological disease (pulmonary cancer, breast cancer, ovarian cancer, melanoma, thymoma), rheumatoid arthritis. Exclusion Criteria: * refusal consent * patient with neurological disorder compatible with paraneoplastic neurological syndrome or auto-immune encephalitis * patient under guardianship
Where this trial is running
Bron
- Hospices Civils de Lyon — Bron, France (Recruiting)
Study contacts
- Principal investigator: Jerome Honnorat, Pr — Centre de référence des syndromes neurologiques paranéoplasiques et encéphalites auto-immunes, Lyon, France
- Study coordinator: Jerome Honnorat, Pr
- Email: jerome.honnorat@chu-lyon.fr
- Phone: (33) 4 72 35 78 06
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.